Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2025-12-29 @ 2:34 PM
Study NCT ID:
NCT05780151
Status:
COMPLETED
Last Update Posted:
2025-05-29
First Post:
2023-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069036', 'term': 'Insulin Glargine'}], 'ancestors': [{'id': 'D049528', 'term': 'Insulin, Long-Acting'}, {'id': 'D061385', 'term': 'Insulins'}, {'id': 'D010187', 'term': 'Pancreatic Hormones'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Parallel-group, open-label, multi-centre study'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 107}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-07-10', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'completionDateStruct': {'date': '2025-01-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-22', 'studyFirstSubmitDate': '2023-03-08', 'studyFirstSubmitQcDate': '2023-03-21', 'lastUpdatePostDateStruct': {'date': '2025-05-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-03-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-01-21', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Enrolment rates', 'timeFrame': '32 weeks', 'description': 'Time to enrolment from Site activation until last participant enrolled'}, {'measure': 'Retention rates', 'timeFrame': '6 months', 'description': 'Proportion of participants completing the study period'}, {'measure': 'Diversity', 'timeFrame': '10 weeks', 'description': 'Various diversity aspects such as race, ethnicity, socioeconomic status, digital literacy, distance to health care professional, mobility.'}, {'measure': 'Participant satisfaction', 'timeFrame': '6 months', 'description': 'Participant satisfaction measured using a questionnaire just after V2 (baseline), V6 and V9 (EOT)'}, {'measure': 'Site staff satisfaction', 'timeFrame': '6 months', 'description': 'Site staff satisfaction measured using a questionnaire (after study initiation visit \\[SIV\\]), after 3 enrolled participants, after 3 participants completed Week 12 and after last patient last visit (LPLV).'}, {'measure': 'Study cost', 'timeFrame': 'complete trial duration', 'description': 'Absolute cost per participant using a combination of prospective and retrospective measurements'}, {'measure': 'Time of AE (Adverse Event)/ SAE (Serious Adverse Event) occurence to collection', 'timeFrame': '6 months', 'description': 'Time from event occurrence to collection AE/SAE in the eDiary or eCRF (electronic Case Report Form), whichever is applicable.'}, {'measure': 'Treatment adherence', 'timeFrame': '6 months', 'description': "Adherence to the daily insulin injection by means of eDiary analysis in percentage of days of documented intake until participant's EOT."}, {'measure': 'Missing data', 'timeFrame': '9 months', 'description': 'Proportion of missing data on the critical data points (Hb1Ac, Fasting Glucose, Participant satisfaction questionnaire)'}, {'measure': 'Query rate', 'timeFrame': '9 months', 'description': 'Number of queries (both manual and automatic) per participant per arm.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['decentralised clinical trial approach', 'proof-of-concept study'], 'conditions': ['Diabetes Mellitus, Type 2']}, 'referencesModule': {'references': [{'pmid': '40888335', 'type': 'DERIVED', 'citation': 'Zuidgeest MGP, Heath M, Lagerwaard B, van Weelij DR, Rutgrink L, Hanke S, Vedenkannas T, Kosonen T, Collamati S, Fons-Martinez J, Veen D, Gardarsdottir H, Mackenzie IS, Dupont S, Grobbee DE; Trials@Home consortium. Bringing Trial Activities to Participants-The Trials@Home RADIAL Proof-of-Concept Trial Investigating Decentralization of Trials. Clin Pharmacol Ther. 2025 Nov;118(5):1037-1045. doi: 10.1002/cpt.70025. Epub 2025 Sep 1.'}], 'seeAlsoLinks': [{'url': 'http://trialsathome.com', 'label': 'Website Trials@Home project'}]}, 'descriptionModule': {'briefSummary': 'Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®.', 'detailedDescription': 'The proposed study has been designed to compare the scientific and operational quality of fully decentralised and hybrid approaches to a conventional clinical trial approach and evaluate the feasibility of such approaches.\n\nThe primary study objectives are to (1) assess potential benefits of a DCT approach on participant recruitment, retention, diversity, site and participant satisfaction, and cost and (2) to determine acceptability of a DCT approach by measuring variables related to safety oversight, treatment adherence and data quality (missing data and query rate) within the arms that have a different degree of decentralisation.\n\nThe secondary study objective is to determine whether the efficacy of treatment with Toujeo® (insulin glargine 300 U/mL) is within the accepted range within the arms with different degree of decentralisation.\n\nThe design is a parallel-group, open-label, multi-centre study in Europe for patients with Type 2 diabetes mellitus ( T2DM) with glycated haemoglobin (HbA1c) between 7% and 10% and treated with basal insulin as part of their glucose-lowering treatment. The study consists of 2 parts with 3 different arms. Part A has site-based recruitment followed by a 1:1 randomization into a conventional arm and a hybrid arm. Part B has decentralised recruitment, no randomization and consists of a fully remote arm.\n\nThe study will enrol approximately 150 adults in each site-based arm (conventional and hybrid) and approximately 300 in the remote arm, for a total of 600 participants in approximately 5-6 countries. Both Part A and Part B will consist of a screening period (3-6 weeks), a treatment period with open-label Toujeo® (24 weeks) and a follow-up period (2-4 days after end of treatment \\[EOT\\]).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Participant with T2DM diagnosed for at least 1 year before the screening visit (V1).\n2. Participant treated with a stable basal insulin regimen (i.e. type of insulin and time/frequency of the injection), for at least 3 months before the screening visit.\n3. The total daily basal insulin dose should be stable (±20%) for at least 1 month before the screening visit.\n4. Participant treated with ≥1 noninsulin antidiabetic drugs at stable dose in the 3 months before the screening visit.\n5. Signed written informed consent or e-consent depending on the arm.\n6. Participant's mental and physical status allows them to be able to perform their activities of daily living with no or minimal assistance, including the ability to administer injectable insulin and measure their blood glycaemic level.\n7. Willing and able to permit home visits (only for Part A of the study).\n8. Willing and able to comply with study drug receipt, accountability, and return processes and procedures.\n9. Access to tablet/smartphone with Bluetooth functionality.\n10. Access to internet connection that allows remote data entry and, for part B, video conferencing.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Age \\<18 years.\n2. HbA1c at screening visit: \\<7.0% or \\>10.0%.\n3. Patient not willing to self-manage insulin titration algorithm.\n4. Type 1 diabetes mellitus.\n5. Treatment with mixed insulin (premixes), short-acting insulin, fast acting insulin analogues or Toujeo® during the 3 months before the screening visit.\n6. Use of systemic glucocorticoids (excluding topical application or inhaled forms) for two weeks or more within 8 weeks prior to the time of screening.\n7. Any clinically significant abnormality identified at the time of screening, or any condition (including known substance or alcohol abuse, or psychiatric disorder) that in the opinion of the Investigator or any sub-Investigator would make implementation of the protocol or interpretation of the study results difficult or would preclude the safe participation of the participant in this study.\n8. Use of any investigational drug within 1 month or 5 half-lives, whichever is longer, prior to screening visit.\n9. Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.\n10. Participant whom the investigator deems otherwise ineligible (e.g. unable to understand and follow instructions). Reason for ineligibility will be documented.\n11. Pregnant or breastfeeding woman at the time of screening.\n12. Woman of childbearing potential not protected by acceptable method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy (see Section 10.3).\n13. Known hypersensitivity / intolerance to insulin glargine or any of Toujeo® excipients.\n14. Participant who withdraws consent during the screening (participant who is not willing to continue or fails to return).\n15. Despite screening of the participant, enrolment is stopped at the study level."}, 'identificationModule': {'nctId': 'NCT05780151', 'acronym': 'RADIAL', 'briefTitle': 'Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)', 'organization': {'class': 'OTHER', 'fullName': 'UMC Utrecht'}, 'officialTitle': 'Pan-European Proof-of-concept Study Comparing Decentralised Clinical Trial (DCT) and Hybrid Approaches to Conventional Clinical Trial Approaches in Patients With Type 2 Diabetes Mellitus Treated With Toujeo®', 'orgStudyIdInfo': {'id': 'EU-CT number 2022-500449-26-00'}, 'secondaryIdInfos': [{'id': '1006010', 'type': 'OTHER', 'domain': 'Central Ethics Committee UK'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Conventional', 'description': 'In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.\n\nThe conventional arm is modelled after a previous clinical trial with a similar indication and intervention and aims to represent current state-of-the art clinical trial conduct.', 'interventionNames': ['Other: Methodological intervention', 'Drug: Toujeo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Hybrid', 'description': 'In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.\n\nThe hybrid trial design is defined as a trial containing conventional trial elements, such as site-based recruitment and screening visits, as well as decentralised trials elements, such as a remote follow-up period and data collection', 'interventionNames': ['Other: Methodological intervention', 'Drug: Toujeo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Remote', 'description': 'In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.\n\nThe remote arm is fully decentralised and aims to represent future decentralised clinical trial practice using a decentralised recruitment model, intervention period and data collection.', 'interventionNames': ['Other: Methodological intervention', 'Drug: Toujeo']}], 'interventions': [{'name': 'Methodological intervention', 'type': 'OTHER', 'description': 'All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.', 'armGroupLabels': ['Conventional', 'Hybrid', 'Remote']}, {'name': 'Toujeo', 'type': 'DRUG', 'otherNames': ['insulin glargine 300 U/ml'], 'description': "All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.", 'armGroupLabels': ['Conventional', 'Hybrid', 'Remote']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Odense', 'country': 'Denmark', 'facility': 'Steno Diabetes Centre Odense', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'city': 'Odense', 'country': 'Denmark', 'facility': 'Syddansk Universitet', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'city': 'Berlin', 'country': 'Germany', 'facility': 'Studienzentrum Diabetespraxis Dr. Braun', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Dresden', 'country': 'Germany', 'facility': 'Klinische Forschung Dresden GmbH', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'city': 'Leipzig', 'country': 'Germany', 'facility': 'Velocity Clinical Research Leipzig GmbH', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'FutureMeds Soho Health Centre', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'city': 'Blackpool', 'country': 'United Kingdom', 'facility': 'Blackpool Teaching Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'city': 'Leicester', 'country': 'United Kingdom', 'facility': 'University Hospitals Leicester NHS Trust', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'city': 'Newcastle', 'country': 'United Kingdom', 'facility': 'NIHR Patient Recruitment Centre Newcastle, The Newcastle upon Tyne Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 54.21804, 'lon': -5.88979}}], 'overallOfficials': [{'name': 'Mira GP Zuidgeest, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'UMC Utrecht'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mira Zuidgeest', 'class': 'OTHER'}, 'collaborators': [{'name': 'IMI Trials@Home consortium', 'class': 'UNKNOWN'}, {'name': 'Innovative Medicines Initiative', 'class': 'OTHER'}, {'name': 'Sanofi', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'Mira Zuidgeest', 'investigatorAffiliation': 'UMC Utrecht'}}}}